EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer

Chenchu Lin, Thomas L Pulliam, Jenny J Han, Jiaqian Xu, Carlos Vera Recio, Sandi R Wilkenfeld, Yan Shi, Manoj Kushwaha, Sarah Bench, Eduardo Ruiz, Sanjanaa Senthilkumar, Jayasurya Dileep und 8 weitere

Cell Reports · 2025-06 · 44 (6) · 115792

DOI: 10.1016/j.celrep.2025.115792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025-06. Verfasst von Chenchu Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; UTHealth Graduate School of Biomedic…. Hauptthemen laut MEDLINE: Cyclic AMP Response Element-Binding Protein, Prostatic Neoplasms, Castration-Resistant, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Signal Transduction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NLM NIH HHS, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Castration-resistant prostate cancer (CRPC) remains an incurable disease in need of improved treatments. CAMKK2 is an emerging therapeutic target whose oncogenic effects in prostate cancer have, to date, been largely attributed to its activation of AMP-activated protein kinase (AMPK). Here, we demonstrate that CAMKK2 promotes prostate cancer growth through an alternative downstream pathway involving CAMKI and CREB. Unbiased transcriptomics identify CREB-mediated transcription as a CAMKK2-regulated process, findings that we validate using diverse molecular, genetic, and pharmacological approaches in vitro and in vivo. CAMKK2 promotes CREB phosphorylation/activation through CAMKIα independently of AMPK, CAMKIV, or other CAMKI isoforms. Functionally, the CREB family members CREB1 and ATF1 exhibit close redundancy, necessitating co-targeting for optimal anti-tumor efficacy. An inhibitor of CREB1/ATF1 blocks CRPC with minimal side effects. Mechanistically, CAMKK2 and CREB increase CRPC growth through augmenting cholesterol metabolism. Together, these findings identify an oncogenic pathway that could be exploited for the treatment of CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic AMP Response Element-Binding ProteinProstatic Neoplasms, Castration-ResistantCalcium-Calmodulin-Dependent Protein Kinase KinaseSignal TransductionCholesterolMaleHumansAnimalsMiceCell Line, TumorCell ProliferationPhosphorylationAMP-Activated Protein Kinases

Stichwörter der Autor:innen

AMPKCAMKICAMKK2CP: CancerCP: MetabolismCREBandrogen receptorcholesterolmetabolismprostate cancer

Substanzen

Cyclic AMP Response Element-Binding ProteinCalcium-Calmodulin-Dependent Protein Kinase KinaseCAMKK2 protein, humanCholesterolCREB1 protein, humanAMP-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center Houston…
  • Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
  • Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Mayo Clinic Alix School of Medicine, Phoenix, AZ 85054, USA.
  • Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; McKetta Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.

Förderung

  • NCI NIH HHS
  • NLM NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health National Cancer Institute
  • National Library of Medicine
  • The University of Texas MD Anderson Cancer Center
  • National Institutes of Health
  • University of Texas Health Science Center at Houston

Zitieren

APA

Lin, C., Pulliam, T. L., Han, J. J., Xu, J., Recio, C. V., Wilkenfeld, S. R., Shi, Y., Kushwaha, M., Bench, S., Ruiz, E., Senthilkumar, S., Dileep, J., Shepherd, P. D. A., Navone, N. M., Klekers, A. R., Whitley, E. M., Ittmann, M. M., Eberlin, L. S., Wang, W., & Frigo, D. E. (2025). Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Reports, 44(6), 115792. https://doi.org/10.1016/j.celrep.2025.115792

Vancouver

Lin C, Pulliam TL, Han JJ, Xu J, Recio CV, Wilkenfeld SR, et al. Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Reports. 2025;44(6):115792. doi:10.1016/j.celrep.2025.115792

BibTeX
@article{Lin2025,
  author = {Lin, Chenchu and Pulliam, Thomas L and Han, Jenny J and Xu, Jiaqian and Recio, Carlos Vera and Wilkenfeld, Sandi R and Shi, Yan and Kushwaha, Manoj and Bench, Sarah and Ruiz, Eduardo and Senthilkumar, Sanjanaa and Dileep, Jayasurya and Shepherd, Peter D A and Navone, Nora M and Klekers, Albert R and Whitley, Elizabeth M and Ittmann, Michael M and Eberlin, Livia S and Wang, Wenyi and Frigo, Daniel E},
  title = {Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer},
  journal = {Cell Reports},
  year = {2025},
  volume = {44},
  number = {6},
  pages = {115792},
  doi = {10.1016/j.celrep.2025.115792}
}
Kostenlos starten →